Similar analysis of metabolites in control and vemurafenib-treated patient-derived Mel 14-108 (BRAFV600E) and Mel 14-089 (BRAF wild-type) melanomas showed that vemurafenib treatment significantly impacted pathways related to glycine, serine, and threonine metabolism, PPP, NAD metabolism, pyruvate metabolism, arginine, glycolysis, and CoA biosynthesis only in BRAF mutant Mel 14-108 cells, while vemurafenib had no effect on these processes in BRAF wild-type Mel 14-089 cells (Figure S7 and Table S1A,B). Here, BRAF is linked to melanoma.